Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 2/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11903082 | 0.82 | CYP3A4 (0.34) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL15597610 | 0.82 | CSNK2A2 (0.32) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL129625 | 0.82 | HTT (0.34) | HRH2HRH1HRH4HRH3TDP1 | |
| SCHEMBL5019516 | 0.79 | PRKACA (0.38) | HRH2HRH1HRH4HRH3TDP1 | |
| SCHEMBL24292894 | 0.77 | CHRM4 (0.35) | HRH2HRH1HRH4HRH3TDP1 | |
| SCHEMBL532652 | 0.77 | HIF1A (0.33) | — | |
| SCHEMBL15354464 | 0.77 | KDM4A (0.50) | HRH2HRH1HRH4HRH3TDP1 | |
| SCHEMBL7073447 | 0.76 | HRH3 (0.41) | HRH2HRH1HRH4HRH3TDP1 | |
| SCHEMBL5019517 | 0.76 | KDM4A (0.34) | HRH2HRH1HRH4HRH3 | |
| SCHEMBL4419597 | 0.74 | PAK1 (0.41) | HRH4HRH3PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513928-B1 | A BANK OF STEM CELLS FOR PRODUCING CELLS FOR TRANSPLANTATION HAVING HLA ANTIGENS MATCHING THOSE OF TRANSPLANT RECIPIENTS, AND METHODS FOR MAKING AND USING SUCH A STEM CELL BANK | ADVANCED CELL TECH INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20190225937-A1 | BANK OF STEM CELLS FOR PRODUCING CELLS FOR TRANSPLANTATION HAVING HLA ANTIGENS MATCHING THOSE OF TRANSPLANT RECIPIENTS AND METHODS FOR MAKING AND USING SUCH A STEM CELL BANK | ADVANCED CELL TECH INC (US) | 2019-07-25 | — | — | US | disclosed |
| US-20130276154-A1 | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank | ADVANCED CELL TECHNOLOGY, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1513928-A2 | A BANK OF STEM CELLS FOR PRODUCING CELLS FOR TRANSPLANTATION HAVING HLA ANTIGENS MATCHING THOSE OF TRANSPLANT RECIPIENTS, AND METHODS FOR MAKING AND USING SUCH A STEM CELL BANK | Advanced Cell Technology, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040091936-A1 | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank | ADVANCED CELL TECHNOLOGY, INC. | 2004-05-13 | — | — | US | disclosed |
| WO-2003100018-A2 | A BANK OF STEM CELLS FOR TRANSPLANTATION | ADVANCED CELL TECHNOLOGY, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | HRH2 4628/4885HRH1 4012/4885HRH4 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.